Since a continued investigation is recommended in the treatment pathway of HPV-positive head and neck cancer, detailed clinical information is needed to prove the effects of combined EGFR expression and HPV infections on clinical outcomes in lung cancer. This evidence concerns the gene EGFR and lung cancer.